Progress and Prospects on Vaccine Development against SARS-CoV-2
In December 2019, the outbreak of pneumonia caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a serious pandemic in China and other countries worldwide. So far, more than 460,000 confirmed cases were diagnosed in nearly 190 countries, causing glo...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-03-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/8/2/153 |
| _version_ | 1797626387518980096 |
|---|---|
| author | Jinyong Zhang Hao Zeng Jiang Gu Haibo Li Lixin Zheng Quanming Zou |
| author_facet | Jinyong Zhang Hao Zeng Jiang Gu Haibo Li Lixin Zheng Quanming Zou |
| author_sort | Jinyong Zhang |
| collection | DOAJ |
| description | In December 2019, the outbreak of pneumonia caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a serious pandemic in China and other countries worldwide. So far, more than 460,000 confirmed cases were diagnosed in nearly 190 countries, causing globally over 20,000 deaths. Currently, the epidemic is still spreading and there is no effective means to prevent the infection. Vaccines are proved to be the most effective and economical means to prevent and control infectious diseases. Several countries, companies, and institutions announced their programs and progress on vaccine development against the virus. While most of the vaccines are under design and preparation, there are some that have entered efficacy evaluation in animals and initial clinical trials. This review mainly focused on the progress and our prospects on field of vaccine development against SARS-CoV-2. |
| first_indexed | 2024-03-11T10:09:42Z |
| format | Article |
| id | doaj.art-3a6937c286234e93acdf8311bfeb6e4c |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-11T10:09:42Z |
| publishDate | 2020-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-3a6937c286234e93acdf8311bfeb6e4c2023-11-16T14:36:13ZengMDPI AGVaccines2076-393X2020-03-018215310.3390/vaccines8020153Progress and Prospects on Vaccine Development against SARS-CoV-2Jinyong Zhang0Hao Zeng1Jiang Gu2Haibo Li3Lixin Zheng4Quanming Zou5National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy and Laboratory Medicine, Third Military Medical University, Chongqing 400038, ChinaNational Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy and Laboratory Medicine, Third Military Medical University, Chongqing 400038, ChinaNational Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy and Laboratory Medicine, Third Military Medical University, Chongqing 400038, ChinaNational Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy and Laboratory Medicine, Third Military Medical University, Chongqing 400038, ChinaLaboratory of the Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USANational Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy and Laboratory Medicine, Third Military Medical University, Chongqing 400038, ChinaIn December 2019, the outbreak of pneumonia caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a serious pandemic in China and other countries worldwide. So far, more than 460,000 confirmed cases were diagnosed in nearly 190 countries, causing globally over 20,000 deaths. Currently, the epidemic is still spreading and there is no effective means to prevent the infection. Vaccines are proved to be the most effective and economical means to prevent and control infectious diseases. Several countries, companies, and institutions announced their programs and progress on vaccine development against the virus. While most of the vaccines are under design and preparation, there are some that have entered efficacy evaluation in animals and initial clinical trials. This review mainly focused on the progress and our prospects on field of vaccine development against SARS-CoV-2.https://www.mdpi.com/2076-393X/8/2/153SARS-CoV-2vaccineadjuvantanimal model |
| spellingShingle | Jinyong Zhang Hao Zeng Jiang Gu Haibo Li Lixin Zheng Quanming Zou Progress and Prospects on Vaccine Development against SARS-CoV-2 Vaccines SARS-CoV-2 vaccine adjuvant animal model |
| title | Progress and Prospects on Vaccine Development against SARS-CoV-2 |
| title_full | Progress and Prospects on Vaccine Development against SARS-CoV-2 |
| title_fullStr | Progress and Prospects on Vaccine Development against SARS-CoV-2 |
| title_full_unstemmed | Progress and Prospects on Vaccine Development against SARS-CoV-2 |
| title_short | Progress and Prospects on Vaccine Development against SARS-CoV-2 |
| title_sort | progress and prospects on vaccine development against sars cov 2 |
| topic | SARS-CoV-2 vaccine adjuvant animal model |
| url | https://www.mdpi.com/2076-393X/8/2/153 |
| work_keys_str_mv | AT jinyongzhang progressandprospectsonvaccinedevelopmentagainstsarscov2 AT haozeng progressandprospectsonvaccinedevelopmentagainstsarscov2 AT jianggu progressandprospectsonvaccinedevelopmentagainstsarscov2 AT haiboli progressandprospectsonvaccinedevelopmentagainstsarscov2 AT lixinzheng progressandprospectsonvaccinedevelopmentagainstsarscov2 AT quanmingzou progressandprospectsonvaccinedevelopmentagainstsarscov2 |